Dareway(SH:688579)2022-10-20 16:00Financial Performance - The company's operating revenue for Q3 2022 was ¥157,226,981.75, representing a year-on-year increase of 32.18%[5] - The net profit attributable to shareholders for Q3 2022 was ¥37,418,188.12, a significant increase of 153.77% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥32,405,714.50, up 162.96% year-on-year[5] - The basic earnings per share for Q3 2022 was ¥0.0935, reflecting a growth of 153.39% year-on-year[6] - The total operating profit for Q3 2022 was ¥25,769,215.89, an increase from ¥22,958,828.61 in Q3 2021, representing a growth of approximately 7.9%[31] - The net profit for Q3 2022 reached ¥25,895,689.76, compared to ¥25,215,330.59 in Q3 2021, indicating an increase of about 2.7%[31] Research and Development - The total R&D investment for Q3 2022 was ¥31,253,675.22, accounting for 19.88% of operating revenue, a decrease of 3.77 percentage points compared to the previous year[6] - Research and development expenses for the first three quarters of 2022 amounted to CNY 76,129,053.41, an increase from CNY 72,232,747.23 in the previous year[22] - Research and development expenses increased to 72,967,795.20 RMB from 69,055,787.54 RMB year-over-year[30] Cash Flow and Assets - The cash flow from operating activities for the year-to-date was negative at -¥115,855,561.24, indicating a decline in cash flow due to delayed sales collections[6] - The company's cash and cash equivalents decreased to RMB 261,030,068.99 from RMB 494,040,957.76, representing a decline of about 47.1%[17] - The cash flow from operating activities for the first nine months of 2022 was negative at -¥112,381,435.69, worsening from -¥45,963,948.21 in the same period of 2021[33] - Cash and cash equivalents at the end of Q3 2022 totaled ¥245,979,382.61, down from ¥392,079,001.26 at the end of Q3 2021, a decrease of approximately 37.4%[34] - The total cash inflow from operating activities for the first nine months of 2022 was ¥273,749,862.26, down from ¥356,980,799.94 in the same period of 2021, reflecting a decline of about 23.3%[33] - The total cash outflow from investing activities for the first nine months of 2022 was ¥81,817,669.01, compared to ¥170,410,235.14 in the same period of 2021, indicating a decrease of approximately 52.0%[33] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,703[12] - Major shareholders include Shandong University Capital Operation Co., Ltd., holding 29.58% of shares, and Guoshou Chengda (Shanghai) Health Industry Equity Investment Center, holding 17.09%[12] - The company has not disclosed any related party relationships among its top shareholders, indicating a lack of known connections[17] Liabilities and Equity - Total liabilities as of the end of the third quarter of 2022 were CNY 317,330,259.06, down from CNY 448,035,470.59 at the end of the previous year[22] - The company's total current liabilities decreased to RMB 170,696,722.80 from RMB 253,412,730.93, a reduction of approximately 32.6%[18] - Total equity attributable to shareholders was CNY 1,262,100,327.34, slightly down from CNY 1,273,136,872.31 in the previous year[22] - The total equity decreased to 1,268,714,970.32 RMB from 1,278,414,413.89 RMB year-over-year[30] Future Outlook - The company plans to continue focusing on market expansion and new product development to drive future growth[22] - The company has not reported any new products or technologies in this quarter, focusing instead on improving cash flow management and operational efficiency[31]